Among children and young people with type 1 diabetes in England, a longer disease duration and higher systolic blood pressure are independently linked to a greater risk for diabetic retinopathy. Medscape News UK
Tag: Diabetes & Endocrinology
Ultrasound May Help Predict Graves Orbitopathy Risk
Researchers test a new risk score using ultrasound to screen for orbitopathy, a complication estimated to occur in more than 25% of people with Graves disease. Medscape Medical News
The Expanding Use of CGM for Diabetes
Dr Anne Peters discusses the expanding use of continuous glucose monitoring in people with diabetes. Medscape Diabetes & Endocrinology
Duration and Age Tied to Different Complication Risks in T1D
In patients with childhood onset T1D, a longer diabetes duration is mainly linked to a higher risk for retinopathy, and older age more strongly predicts albuminuria after over 30 years of follow up. Medscape News UK
Delayed TED Underrecognized Following MS Treatment
Reports of cases detail the development of thyroid eye disease 3-5 years following treatment of MS with immunomodulatory therapy including alemtuzumab. Medscape Medical News
Are GLP-1 Receptor Agonists Safe for the Eyes?
Do their associations with nonarteritic anterior ischemic optic neuropathy and other adverse outcomes make these drugs more risky than beneficial? Medscape Global
US FDA Greenlights Viridian’s Thyroid Eye Disease Drug
The U.S. Food and Drug Administration has approved Viridian Therapeutics’ drug to treat patients with thyroid eye disease, the company said on Friday. Reuters Health Information
No Increased Retinopathy Risk Seen With Tirzepatide
No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide. Medscape Medical News
Gestational Diabetes May Raise Future Retinopathy Risk
In women with diabetes, a history of gestational diabetes is associated with a higher risk for diabetic retinopathy, with risk increasing as gestational diabetes severity increases. Medscape Medical News
Medscape Endocrinologist Compensation Report 2026
US endocrinologists report their 2025 compensation and satisfaction with it. Differences in doctor pay by gender, racial and ethnic group, and medical specialty are revealed. Medscape
GLP-1 Drugs May Modestly Raise Optic Neuropathy Risk in T2D
GLP-1 therapy is linked to a modestly increased risk for nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitors in veterans with type 2 diabetes. Medscape Medical News
A Preliminary Look at Subtyping People With Type 2 Diabetes
Dr Anne Peters discusses the varying subtypes of diabetes. Medscape Diabetes & Endocrinology
GLP-1 Drugs Under Scrutiny: How Real Are the Risks?
Gastrointestinal adverse effects remain a key barrier to continued use of these agents, with slower dose titration emerging as a strategy to improve tolerability and adherence. Medscape News Europe
Myth of the Month: GLP-1s Have Many Dangerous Side Effects
Dr Paauw debunks concerns about thyroid cancer, suicide, and pancreatitis. Medscape Internal Medicine
Vascular Complications Tied to Poor CRC Outcomes in Diabetes
In patients with colorectal cancer undergoing major resection surgery, a greater severity of diabetes-related vascular complications is linked to poorer postoperative outcomes, including mortality. Medscape News UK
Eye Condition Risk Elevated With Semaglutide, but Still Low
New VA database study is the latest to find a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy. Medscape Medical News
Mary Tyler Moore Initiative Combats Diabetic Retinal Disease
Moore’s widower, S. Robert Levine, MD, launched the nonprofit in his famous wife’s memory to advance research and accelerate treatment. Medscape Medical News
Secukinumab Fails to Show Benefit in Graves’ Orbitopathy
Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves’ orbitopathy, according to the ORBIT study. Medscape News UK
Veligrotug Shows Promise for Treating Thyroid Eye Disease
The THRIVE and THRIVE-2 clinical trials showed significant improvements in proptosis and diplopia in active as well as chronic thyroid eye disease, earning FDA Breakthrough Therapy designation. Medscape Medical News
MHRA Approves First UK Treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency has approved teprotumumab, the first treatment to be licensed in the UK for adults with thyroid eye disease. Medscape News UK